Home

Pasithea Therapeutics Corp. - Common Stock (KTTA)

2.2400
-0.0100 (-0.44%)

Pasithea Therapeutics Corp is a biotechnology company focused on the development of innovative therapies for the treatment of psychiatric and neurological disorders

The company is committed to leveraging advanced scientific research and cutting-edge technologies to create new treatment options that address unmet medical needs in these challenging areas. Pasithea aims to improve the quality of life for patients suffering from conditions such as depression and anxiety by exploring novel approaches in drug discovery and development. Through its work, Pasithea seeks to make a meaningful impact on mental health care and enhance overall well-being in affected individuals.

SummaryNewsPress ReleasesChartHistoricalFAQ
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQKTTA),NASDAQ:SWTXNASDAQSWTX)(NASDAQ:DAWNNASDAQDAWN,(NASDAQ:VSTMNASDAQ),(NASDAQ:KNTEKNTE) EQNX::TICKER_END
Via FinancialNewsMedia · June 1, 2023
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest external stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement recommending stockholders vote on the WHITE proxy card to remove the Company’s Board of Directors (the “Board”) at the upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for Friday, December 9th, 2022:
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest external stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement in connection with its efforts to remove the Company’s Board of Directors (the “Board”) at the upcoming Special Meeting of Stockholders (the “Special Meeting”) on Tuesday, November 29, 2022:
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
Learn More about Pasithea Therapeutics by gaining access to the latest research report
Via TheNewswire.com · October 3, 2022
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement regarding the Company's recently announced dilutive acquisition of AlloMek Therapeutics, LLC (“AlloMek”). As a reminder, the Investor Group has successfully requisitioned Pasithea’s Board of Directors (the “Board") to call a Special Meeting of Stockholders (the “Special Meeting”).
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide markets. The COVID-19 pandemic has impacted the whole drug industry’s inventory network. It will also increase interest in the global central […]
Via FinancialNewsMedia · October 12, 2022
Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022
Ron Bauer has an impressive track record in helping founders and entrepreneurs raise money and go public. With over 20 years as a seasoned founder and entrepreneur himself, he’s spent decades building up an impressive resume. He operates through his main company in London which is Theseus Capital, and it is through Theseus that he’s recently begun advising and mentoring the next generation of dynamic founders and startup entrepreneurs.
Via Get News · September 29, 2022
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today announced that they sent the below letter to the Company’s Board of Directors.
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are one of the largest stockholders of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today announced that the Investor Group has received sufficient support from its fellow stockholders to request the call of a Special Meeting of Stockholders (the “Special Meeting”). Accordingly, the Investor Group has formally commenced the process of calling the Special Meeting and issued the following statement:
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are one of the largest stockholders of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the following letter to their fellow stockholders:
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal loss. According to the Multiple Sclerosis International Federation, the number of people with […]
Via FinancialNewsMedia · August 11, 2022
Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are one of the largest stockholders of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the following open letter to their fellow stockholders:
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the following statement regarding the Company's dilutive and reactionary acquisition of Alpha-5 integrin, LLC (“Alpha-5”):
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It includes many rare neurological disease disorders like Alzheimer’s disease, Parkinson’s disease and Multiple Sclerosis. It is also associated with aging and Traumatic brain injury. According to […]
Via FinancialNewsMedia · June 22, 2022
PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article
Pasithea Therapeutics’ (NASDAQKTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes article. The piece, titled “You May Soon Find Mental Health Help from Psychedelic Drug-Assisted Psychotherapy in the Metaverse,” discusses record levels of mental health issues driven by the pandemic, social unrest, partisan politics, cable news, social media and Russia’s war against Ukraine. To learn about ways to help with this mental health epidemic, the article’s author and Forbes’ senior contributor, Jack Kelly, spoke with Dr. Marques. He shared the promising innovation of psychedelic, drug-assisted psychotherapy—the medically approved use of MDMA, psilocybin and LSD as a component of elevated psychotherapy programs.
Via Investor Brand Network · May 5, 2022
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric and neurological disorders are driving the market for central nervous system (CNS) therapeutic. According to WHO, the global economy loses due to depression and […]
Via FinancialNewsMedia · March 8, 2022
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
Palm Beach, FL –– February 3, 2022  – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination, inflammation, and degenerative changes such as progressive brain and spinal cord atrophy, neuroaxonal loss, and others. According to the Multiple Sclerosis Trust, 2.5 million people in […]
Via FinancialNewsMedia · February 3, 2022
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Palm Beach, FL –– February 24, 2022  – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy – the medically approved use of MDMA, psilocybin, and LSD as […]
Via FinancialNewsMedia · February 24, 2022
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market. The pandemic is predicted to have a long and short term impact on the individual’s mental illness, given the hurdles faced during the crisis, such […]
Via FinancialNewsMedia · November 23, 2021
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion therapy for the treatment of mental health disorders and there is also a rising number of local manufacturers and increasing R&D activities in anesthetics […]
Via FinancialNewsMedia · November 17, 2021
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been legal for quite some time. Ketamine was originally popularized as an anesthetic. However, it has been used off-label for many […]
Via FinancialNewsMedia · October 27, 2021
Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the medical cost of mental health conditions is estimated to rise to $6 trillion by 2030. The prevalence of mental health disorders has risen exponentially but […]
Via FinancialNewsMedia · October 14, 2021
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus, pharmaceutical companies are investing a huge amount of money for novel drug R&D and launches for psychiatric and neurological disorders. The development and discovery of new […]
Via FinancialNewsMedia · October 11, 2021
SmallCapsDaily: Pasithea Therapeutics Emerges as a Major Player in the Biotech Industry
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · October 4, 2021